Literature DB >> 24084141

Investigation of osteopontin levels and genomic variation of osteopontin and its receptors in Type 1 diabetes mellitus.

Z Karamizadeh1, E Kamali Sarvestani, F Saki, H Karamifar, G H Amirhakimi, M H Namavar Shooshtarian, S Ashkani-Esfahani.   

Abstract

BACKGROUND: Failure in self-tolerance towards β-cells in diabetes mellitus (DM) pathogenesis involves a series of complex events that are governed by environmental and genetic factors. Considering the importance of osteopontin (OPN) in T-helper-1 (Th1) cells development, the aim of this study was to evaluate the serum level and gene polymorphism of OPN in Iranian Type 1 diabetic (T1DM) children.
METHODS: In this case-control study, 87 T1DM children and 86 healthy ones were enrolled. Blood samples of both groups were checked for OPN level. The single nucleotide polymorphisms (SNP) were genotyped by RFLP analysis for OPN rs1126772, its receptor integrin α4 (ITGA4) rs 1449263, and CD44 rs8193.
RESULTS: Serum levels of OPN in diabetic children were significantly higher in cases compared to the control group (p=0.023), but there was no significant relationship between OPN rs1126772 (p=0.79), its receptor integrin α4 (p=0.31), and CD44 rs8193 (p=0.45), and T1DM.
CONCLUSION: Higher amounts of OPN were seen in T1DM children. It is assumed that OPN might have inducing effects on T1DM development, particularly when genetically susceptible individuals are predisposed by an environmental insult. However, the 3 SNPs of OPN and its receptors did not show noticeable association with T1DM. The power of our study (~19%) was insufficient to observe any significant statistical difference between the groups; moreover, this study does not exclude the possibility of association of other SNPs of OPN and its receptors with this disease, and more studies are needed to clarify the issue.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24084141     DOI: 10.3275/9098

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   5.467


  37 in total

1.  Behçet's disease exhibits an increased osteopontin serum level in active stage but no association with osteopontin and its receptor gene polymorphisms.

Authors:  Mingliang Chu; Peizeng Yang; Shengping Hou; Fuzhen Li; Yuanyuan Chen; Aize Kijlstra
Journal:  Hum Immunol       Date:  2011-04-08       Impact factor: 2.850

2.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

3.  Report of the expert committee on the diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

Review 4.  Osteopontin: a versatile regulator of inflammation and biomineralization.

Authors:  C M Giachelli; S Steitz
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

5.  Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice.

Authors:  Maki Nakayama; Norio Abiru; Hiroaki Moriyama; Naru Babaya; Edwin Liu; Dongmei Miao; Liping Yu; Dale R Wegmann; John C Hutton; John F Elliott; George S Eisenbarth
Journal:  Nature       Date:  2005-05-12       Impact factor: 49.962

6.  Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus.

Authors:  C K Wong; L C W Lit; L S Tam; E K Li; C W K Lam
Journal:  Rheumatology (Oxford)       Date:  2005-02-10       Impact factor: 7.580

7.  An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus.

Authors:  A C Forton; M A Petri; D Goldman; K E Sullivan
Journal:  Hum Mutat       Date:  2002-04       Impact factor: 4.878

8.  Enhanced expression of osteopontin by high glucose. Involvement of osteopontin in diabetic macroangiopathy.

Authors:  M Takemoto; K Yokote; M Yamazaki; A L Ridall; W T Butler; T Matsumoto; K Tamura; Y Saito; S Mori
Journal:  Ann N Y Acad Sci       Date:  2000-05       Impact factor: 5.691

9.  The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease.

Authors:  Jürgen Glas; Julia Seiderer; Corinna Bayrle; Martin Wetzke; Christoph Fries; Cornelia Tillack; Torsten Olszak; Florian Beigel; Christian Steib; Matthias Friedrich; Julia Diegelmann; Darina Czamara; Stephan Brand
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

10.  Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction.

Authors:  Shizhong Han; Joel M Guthridge; Isaac T W Harley; Andrea L Sestak; Xana Kim-Howard; Kenneth M Kaufman; Bahram Namjou; Harshal Deshmukh; Gail Bruner; Luis R Espinoza; Gary S Gilkeson; John B Harley; Judith A James; Swapan K Nath
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

View more
  4 in total

1.  The osteopontin transgenic mouse is a new model for Sjögren's syndrome.

Authors:  Sehba Husain-Krautter; Jill M Kramer; Wentian Li; Benchang Guo; Thomas L Rothstein
Journal:  Clin Immunol       Date:  2015-01-05       Impact factor: 3.969

2.  The Role of Osteopontin in the Pathogenesis and Complications of Type 1 Diabetes Mellitus in Children.

Authors:  Mohamed A Talat; Laila Metwaly Sherief; Hosam Fathy El-Saadany; Anwar Ahmed Rass; Rabab M Saleh; Maha Mahmoud Hamed Sakr
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-06-29

3.  The association between osteopontin gene polymorphisms, osteopontin expression and sarcoidosis.

Authors:  Hadas Lavi; Miri Assayag; Assaf Schwartz; Nissim Arish; Zvi G Fridlender; Neville Berkman
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

Review 4.  Association between Genetic Variants and Diabetes Mellitus in Iranian Populations: A Systematic Review of Observational Studies.

Authors:  Mehrnoosh Khodaeian; Samaneh Enayati; Ozra Tabatabaei-Malazy; Mahsa M Amoli
Journal:  J Diabetes Res       Date:  2015-10-26       Impact factor: 4.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.